menu
    • menu
    [{"orgOrder":0,"company":"Asceneuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ASN51","moa":"Beta-N-acetylhexosaminidase (OGA)","graph1":"Neurology","graph2":"Phase II","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Asceneuron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Asceneuron \/ Inapplicable"},{"orgOrder":0,"company":"Asceneuron","sponsor":"EQT Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"ASN51","moa":"Beta-N-acetylhexosaminidase (OGA)","graph1":"Neurology","graph2":"Phase II","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Asceneuron \/ EQT Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Asceneuron \/ EQT Life Sciences"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Asceneuron | Neuroscience Trials Australia","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ASN51","moa":"Beta-N-acetylhexosaminidase (OGA)","graph1":"Neurology","graph2":"Phase II","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Asceneuron \/ Asceneuron | Neuroscience Trials Australia","highestDevelopmentStatusID":"8","companyTruncated":"Asceneuron \/ Asceneuron | Neuroscience Trials Australia"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Hammersmith Medicines Research | Invicro","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ASN51","moa":"Beta-N-acetylhexosaminidase (OGA)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Asceneuron \/ Hammersmith Medicines Research | Invicro","highestDevelopmentStatusID":"6","companyTruncated":"Asceneuron \/ Hammersmith Medicines Research | Invicro"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Hammersmith Medicines Research","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ASN51","moa":"Beta-N-acetylhexosaminidase (OGA)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Asceneuron \/ Hammersmith Medicines Research","highestDevelopmentStatusID":"6","companyTruncated":"Asceneuron \/ Hammersmith Medicines Research"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fluvoxamine","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asceneuron \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asceneuron \/ Inapplicable"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ASN90","moa":"OGA","graph1":"Neurology","graph2":"Phase I","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asceneuron \/ Ferrer Internacional","highestDevelopmentStatusID":"6","companyTruncated":"Asceneuron \/ Ferrer Internacional"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ASN90","moa":"OGA","graph1":"Neurology","graph2":"Preclinical","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asceneuron \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Asceneuron \/ Inapplicable"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ASN120290","moa":"OGA","graph1":"Neurology","graph2":"Phase I","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asceneuron \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Asceneuron \/ Inapplicable"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"ASN51","moa":"Beta-N-acetylhexosaminidase (OGA)","graph1":"Neurology","graph2":"Preclinical","graph3":"Asceneuron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asceneuron \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"4","companyTruncated":"Asceneuron \/ Michael J. Fox Foundation for Parkinson\u2019s Research"}]

    Find Clinical Drug Pipeline Developments & Deals by Asceneuron

    Menu

    Asceneuron

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASN51

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of ASN51 in Adults With Early Alzheimer's Disease

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 06, 2024

                            Lead Product(s) : ASN51

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASN51

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : EQT Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Asceneuron raises $100M series C for ph. 2 Alzheimer's trial

                            Details : The Funds will be used to progress lead asset ASN51, an oral small molecule OGA inhibitor, into Phase 2 clinical development for the treatment of Alzheimer’s disease.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : ASN51

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : EQT Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASN51

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Hammersmith Medicines Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Positron Emission Tomography Study in Healthy Subjects to Determine the Relationship Between Plasma Concentrat...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 30, 2024

                            Lead Product(s) : ASN51

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Hammersmith Medicines Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluvoxamine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 30, 2024

                            Lead Product(s) : Fluvoxamine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASN90

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Ferrer Internacional

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ferrer Acquires Worldwide Rights to ASN90, an O-GlcNAcase Inhibitor From Asceneuron, Exclusively to Treat Prog...

                            Details : Under the licensing agreement, Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90, an O-GlcNAcase inhibitor, in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 22, 2023

                            Lead Product(s) : ASN90

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Ferrer Internacional

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASN51

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Hammersmith Medicines Research | Invicro

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PET Study of Repeated ASN51 in Healthy Volunteers

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 13, 2023

                            Lead Product(s) : ASN51

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Hammersmith Medicines Research | Invicro

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASN51

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkins...

                            Details : The grant will fund a preclinical proof-of-concept study to assess the disease-modifying properties of Asceneuron’s OGA inhibitor ASN51 in a preclinical model of inherited PD.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 05, 2022

                            Lead Product(s) : ASN51

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASN90

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Asceneuron Publishes Pioneering Preclinical Efficacy Data on its Novel Clinical Molecule ASN90 in Both Alzheim...

                            Details : Findings published demonstrated increased survival in preclinical model of Alzheimer's disease after administration of clinical molecule ASN90, an O–GlcNAcase inhibitor, as well as significant motor impairment and astrogliosis effect in a Parkinson's m...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 04, 2022

                            Lead Product(s) : ASN90

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASN120290

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences

                            Details : ASN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathic disease, progressive supranuclear palsy (PSP), and was granted Orphan Drug Designation by the US FDA for the treatment of Progressive Supranuclear Palsy (PSP).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 30, 2021

                            Lead Product(s) : ASN120290

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed

                            Asceneuron

                            Switzerland arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASN51

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Asceneuron | Neuroscience Trials Australia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subject...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 18, 2021

                            Lead Product(s) : ASN51

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Asceneuron | Neuroscience Trials Australia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth